Experience in the use of remdesivir in patients with SARS-CoV-2 pneumonia

Abstract

ObjectiveTo describe the effectiveness and safety of remdesivir in patients with SARS-CoV-2 pneumonia in real-world clinical practice conditions. MethodRetrospective observational study that included all adults with SARS-CoV-2 pneumonia admitted at the Moisés Broggi Hospital and treated with remdesivir between July 1st and November 7th, 2020. Efficacy outcomes were time to recovery, 28-day mortality, length of hospital stay, and the need of mechanical ventilation after treatment. The main safetyrelated endpoint was elevation of transaminases after treatment. ResultsA total of 111 patients were included of whom 97 (87.4%) were receiving low-flow oxygen therapy. Median time to recovery was 9 days [6-14]. Seven patients (6.3%) died at 28 days’ follow-up. Median length of hospital stay was 12 days [9-22] and 15 patients (13.5%) needed mechanical ventilation after treatment with remdesivir. Severe hypertransaminasemia was observed in 4 patients (4%). ConclusionsClinical outcomes of patients with SARS-CoV-2 pneumonia on low-flow oxygen therapy treated with remdesivir were similar to those published in clinical trials, both in terms of time to recovery and 28-day mortality.